Related Experiment Video
Updated: Jan 10, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Cancer-Associated Fibroblasts Promote Imatinib Resistance in Gastrointestinal Stromal Tumors through PGK1-Mediated
Chao Li1, Tianhong Teng2, Xiaohan Lin1,3
1Department of General Surgery, Zhongshan Hospital, Fudan University School of Medicine, Shanghai, China.
None:
Gastrointestinal stromal tumors (GIST), the most common sarcomas of the gastrointestinal tract, are primarily driven by c-KIT or PDGFRA mutations that activate downstream signaling pathways, including PI3K/AKT/mTOR. Whereas imatinib (IM), a first-line tyrosine kinase inhibitor (TKI), is initially effective, resistance develops in ∼50% of patients within 20 months. Second- and third-line TKIs, such as sunitinib and regorafenib, provide limited benefits, highlighting the urgent need to address resistance mechanisms. Previous research has predominantly focused on genetic drivers of resistance and overlooked the role of the tumor microenvironment. In this study, we identified a role for cancer-associated fibroblasts (CAF) in driving IM resistance. Specifically, TGFβ1 secreted by CAFs amplified cellular communication network factor 2 (CCN2)/receptor for activated C kinase 1 (Rack1) signaling. The CCN2/Rack1 axis activated PI3K/AKT signaling to induce phosphorylation and mitochondrial translation of phosphoglycerate kinase 1 (PGK1), promoting metabolic reprogramming that supported tumor survival and drug resistance. Coculture models and single-cell RNA sequencing revealed distinct CAF subtypes and showed that CAF-secreted TGFβ1 enhanced glycolysis and inhibited the tricarboxylic acid cycle, fueling GIST progression and secondary resistance. Inversely, CCN2 secreted by GIST cells promoted TGFβ1 production in CAFs. These findings uncover a TGFβ1/CCN2/Rack1/PGK1 mechanism linking CAF-mediated metabolic reprogramming to IM resistance in GISTs. Targeting CAF-GIST interactions and key metabolic pathways presents a promising therapeutic strategy.
Significance:
Cross-talk between cancer-associated fibroblasts and cancer cells promotes metabolic and tumor microenvironmental reprogramming that drives imatinib resistance in gastrointestinal stromal tumors, providing potential targets to overcome resistance and improve therapeutic outcomes.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
06:35A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
Published on: December 22, 2020
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:38Mitogens and the Cell Cycle
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...